# Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis

> **NCT07308392** · PHASE2 · RECRUITING · sponsor: **Fujian Shengdi Pharmaceutical Co., Ltd.** · enrollment: 108 (estimated)

## Conditions studied

- Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis

## Interventions

- **DRUG:** HRS-7249 injection set
- **DRUG:** SHR-1918 injection set
- **DRUG:** HRS-7249 injection placebo set
- **DRUG:** SHR-1918 injection placebo set

## Key facts

- **NCT ID:** NCT07308392
- **Lead sponsor:** Fujian Shengdi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-25
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07308392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07308392, "Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07308392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*